Stay updated on Satralizumab in Thyroid Eye Disease Clinical Trial

Sign up to get notified when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Satralizumab in Thyroid Eye Disease Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T14:51:11.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study content. This indicates an access restriction or server issue preventing viewing the trial details.
    Difference
    0.5%
    Check dated 2026-09-26T16:40:08.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The study record page now shows a 403 Forbidden error, replacing the usual study content. Core study details and attached documents are no longer accessible from this page.
    Difference
    19%
    Check dated 2026-09-19T18:52:45.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    The study record now shows an NIH funding annotation and the latest documentation version (v3.6.6) while the previous version tag (v3.6.5) is removed.
    Difference
    0.1%
    Check dated 2026-08-29T18:55:55.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    The page’s revision label was updated from v3.6.4 to v3.6.5. This indicates a small, internal update to the page build without changing the study content.
    Difference
    0.0%
    Check dated 2026-08-08T10:48:26.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    Results for the SatraGO-1 trial have been posted, and the study record now includes extensive outcome data such as Week 24/48 changes in proptosis, diplopia, CAS, GO-QoL, and safety events. The update also lists the associated documentation and timepoints for result reporting.
    Difference
    5%
    Check dated 2026-08-01T08:50:54.000Z thumbnail image

Stay in the know with updates to Satralizumab in Thyroid Eye Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.